{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal dominant mutations in the human Leucine-Rich Repeat Kinase 2 (LRRK2) gene represent the most common monogenetic cause of Parkinson disease (PD) and increased kinase activity observed in pathogenic mutants of LRRK2 is most likely causative for PD-associated neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as increased kinase activity in LRRK2 mutants leading to neurotoxicity in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses in vitro kinase assays to test the hypothesis of LRRK2 acting as a MAPKKK that phosphorylates MLK substrates, MKK3/6 and MKK4/7, which are involved in cellular stress responses.",
          "judgment": "Yes",
          "reasoning": "In vitro kinase assays are a standard method to assess kinase activity and are applicable to the disease mechanism involving increased kinase activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Kinase assays were performed with purified SF-TAP tagged LRRK2 bound to anti Flag M2 resin and incubated with substrate proteins. Reactions were incubated, stopped, and analyzed by SDS gel-electrophoresis and western blotting. Statistical significance was determined by ANOVA and Tukey’s post-hoc test.",
          "judgment": "Yes",
          "reasoning": "The paper describes standard procedures for kinase assays, including use of specific substrates, incubation conditions, and statistical analysis of results.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The LRRK2 G2019S mutant shows a 3–4-fold higher phosphorylation of MKK6 compared with wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The paper provides direct evidence that the LRRK2 G2019S variant has increased kinase activity towards MKK6, which is relevant to the disease mechanism of PD.",
          "next_step_or_outcome": "PS3_very_strong"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The LRRK2 G2019S variant was found to have a significantly higher kinase activity in vitro compared to wild-type LRRK2, which aligns with the increased neurotoxicity observed in PD patients with this mutation. The functional evidence supports a very strong pathogenic role for the G2019S variant in LRRK2."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal dominant mutations in the human Leucine-Rich Repeat Kinase 2 (LRRK2) gene represent the most common monogenetic cause of Parkinson disease (PD) and increased kinase activity observed in pathogenic mutants of LRRK2 is most likely causative for PD-associated neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as increased kinase activity in LRRK2 mutants leading to neurotoxicity in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses in vitro kinase assays to test the hypothesis of LRRK2 acting as a MAPKKK that phosphorylates MLK substrates, MKK3/6 and MKK4/7, which are involved in cellular stress responses.",
          "judgment": "Yes",
          "reasoning": "In vitro kinase assays are a standard method to assess kinase activity and are applicable to the disease mechanism involving increased kinase activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Kinase assays were performed with purified SF-TAP tagged LRRK2 bound to anti Flag M2 resin and incubated with substrate proteins. Reactions were incubated, stopped, and analyzed by SDS gel-electrophoresis and western blotting. Statistical significance was determined by ANOVA and Tukey’s post-hoc test.",
          "judgment": "Yes",
          "reasoning": "The paper describes standard procedures for kinase assays, including use of specific substrates, incubation conditions, and statistical analysis of results.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The LRRK2 I2020T mutant shows a slight, but significant, increase of about 1.5-fold of wild-type activity in MKK6 phosphorylation.",
          "judgment": "Yes",
          "reasoning": "The paper provides direct evidence that the LRRK2 I2020T variant has increased kinase activity towards MKK6, which is relevant to the disease mechanism of PD.",
          "next_step_or_outcome": "PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 I2020T variant was found to have a modest increase in kinase activity in vitro compared to wild-type LRRK2, which supports a pathogenic role for the I2020T variant in LRRK2. However, the increase in activity is less pronounced compared to the G2019S variant, resulting in a supporting strength rating."
    }
  ]
}